期刊文献+

回复镶嵌现象与隐性营养不良型大疱性表皮松解症治疗的研究进展

Revertant mosaicism and treatment of recessive dystrophic epidermolysis bullosa
原文传递
导出
摘要 隐性营养不良型大疱性表皮松解症是一种遗传性水疱病,由编码Ⅶ型胶原的基因突变引起,对患者生活质量有很大影响,目前治疗多为对症处理,迫切需要更好的治疗方法。近年研究发现,隐性营养不良型大疱性表皮松解症患者存在回复突变所致的片状外观正常皮肤。这种现象称为回复镶嵌现象,也称为天然基因治疗。这一发现开启了回复细胞治疗的可能性,即回复的角质形成细胞体外培养移植到受损皮肤。假如结合患者特异性诱导性多能干细胞方法,可以有机会培养出大片健康皮肤移植物。另外,回复体来源的诱导性多能干细胞还可以分化为造血细胞和间质于细胞,骨髓移植后归巢到水疱区域,即“从皮肤到血细胞,再修复皮肤”。 Recessive dystrophic epidermolysis bullosa (RDEB), an inherited blistering disease caused by mutations in the gene encoding type VII collagen, has a strong impact on patients' quality of life. At present, it is mainly managed by symptomatic treatment, and more effective therapeutic approaches are urgently needed. Recent studies have found the presence of patches of normal-looking skin caused by reverse mutations in patients with RDEB. This phenomenon is called revertant mosaicism, also known as "natural gene therapy". This finding offers the possibility of revertant cell therapy, namely, transplantation of revertant keratinocytes cultured in vitro onto damaged skin. The combination with patient-specific induced pluripotent stem ceils (iPSCs) makes it possible to harvest large sheets of healthy skin graft. Moreover, iPSCs derived from revertant keratinocytes can differentiate into hematopoietic cells and mesenchymal stem cells, which can home to blistering areas after bone marrow transplantation, namely, "from skin to blood ceils, then to repair of skin".
作者 柳琦 张汝芝
出处 《国际皮肤性病学杂志》 2015年第2期103-105,共3页 International Journal of Dermatology and Venereology
基金 国家自然科学基金(81171516)
关键词 营养不良性大疱性表皮松解 皮肤疾病 水疱大疱性 镶嵌现象 遗传现象 多能干细胞 治疗应用 Epidermolysis bullosa dystrophica Skin diseases, vesiculobullous Mosaicism Geneticphenomena Multipotent stem cells Therapeutic uses
  • 相关文献

参考文献16

  • 1Bruckner-Tuderman L. Dystrophic epidermolysis bullosa: pathogenesis and clinical features [J]. Dermatol Clin, 2010, 28 (1): 107-114.
  • 2Almaani N, Nagy N, Liu L, et al. Revertant mosaicism in recessive dystrophic epidermolysis bullosa[J]. J Invest Dermatol, 2010, 130(7): 1937-1940.
  • 3Pasmooij AM, Nijenhuis M, Brander R, et al. Natural gene therapy may occur in all patients with generalized non-Herlitz junctional epidermolysis bullosa with COL17A1 mutations [J]. J Invest Dermatol, 2012, 132(5): 1374-1383.
  • 4Lai-Cheong JE, McGrath JA, Uitto J. Revertant mosaicism in skin: natural gene therapy [J]. Trends Mol Med, 2011, 17(3): 140-148.
  • 5Pasmooij AM, Jonkman MF, Uitto J. Revertant mosaicism in heritable skin diseases: mechanisms of natural gene therapy[J]. Discov Med, 2012, 14(76): 167-179.
  • 6Wada T, Candotti F. Somatic mosaicism in primary immune deficiencies [J]. Curr Opin Allergy Clin Immunol, 2008, 8 (6): 510-514.
  • 7Jonkman MF, Pasmooij AM. Realm of revertant mosaicism expanding[J]. J Invest Dermatol, 2012, 132(3 Pt 1): 514-516.
  • 8Htinefeld C, Mezger M, Kern JS, et al. One goal, different strategies--molecular and cellular approaches for the treatment of inherited skin fragility disorders [J ]. Exp Dermatol, 2013, 22 (3): 162-167.
  • 9Cutlar L, Greiser U, Wang W. Gene therapy: pursuing restoration of dermal adhesion in recessive dystrophic epidermolysis bullosa [J]. Exp Dermatol, 2014, 23(1): 1-6.
  • 10De Luca M, Pellegrini G, Mavilio F. Gene therapy of inherited skin adhesion disorders: a critical overview [J]. Br J Dermatol, 2009, 161(1): 19-24.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部